30805878966_19824f12fd_z

MRI scans can help predict MS patient’s long term prognosis, 15 year study shows

pharmafile | July 25, 2019 | News story | Research and Development CIS, MRI scans, MS, Prognosis, diagnosis, multiple sclerosis, pharma 

MRI scans can predict MS patient’s long term prognosis when they are first diagnosed, according to new research.

In a 15 year study published in the journal Brain, information collected from magnetic resonance imaging (MRI) scans was shown to be able predict long term disease outcomes.

The study, saw researchers look at predictors of key long-term outcomes in 178 patients with clinically isolated syndrome (CIS), a condition in which many patients go on to develop MS.

Advertisement

The patients underwent MRI scans of the brain and spinal cord at study entry and after one and three years.

The patients were then followed up after 15 years to determine the course of their disease. The researchers found that early focal inflammatory disease activity and spinal cord lesions are predictors of long term disease outcomes in patients with relapse-onset MS.

“Established MRI measures, available in routine clinical practice, may be useful in counselling patients with early multiple sclerosis about long-term prognosis, and personalizing treatment plans,” the study says.

Morna Simpkins, Director of the MS Society Scotland, said: “By identifying key factors that appear very early on and indicate how someone’s MS might develop, this study has proved crucial. We’re pleased to have funded the work and look forward to seeing it progress so people living with MS can finally have more certainty about the future.”

Louis Goss

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

blood_test

Johnson & Johnson announces successful results from trial for myeloma treatment

Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …

Bend Bioscience adds commercial spray drying facility to Georgia site

Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …

The Gateway to Local Adoption Series

Latest content